Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGIOS PHARMACEUTICALS, INC. Director's Dealing 2018

Jun 18, 2018

31580_dirs_2018-06-18_d38c185a-3821-47b9-86cd-a28471adc0ad.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2018-06-14

Reporting Person: Foster-Cheek Kaye I (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-06-14 Common stock M 9000 $50.73 Acquired 11200 Direct
2018-06-14 Common stock S 2181 $92.62 Disposed 9019 Direct
2018-06-14 Common stock S 5980 $93.78 Disposed 3039 Direct
2018-06-14 Common stock S 839 $94.30 Disposed 2200 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-06-14 Stock option (right to buy) $50.73 M 9000 Disposed 2027-06-13 Common stock (9000) Direct

Footnotes

F1: This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $92.14 to $93.11. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $93.15 to $94.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $94.21 to $94.63. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F6: This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018.